<div id="readability-page-1"><div><div><p><strong>Eli Lilly and Co. </strong><span>LLY</span> stock is trading lower on Tuesday after its weight loss drug rival, <strong>Novo Nordisk A/S </strong><span>NVO</span>, trimmed its 2025 financial outlook.</p><p>The cut marks the second time this year Novo Nordisk has lowered its guidance.</p><p>Novo Nordisk now projects 2025 sales growth to be 8-14% at constant exchange rates, a notable reduction from its earlier forecast of 13-21%.</p><p>Similarly, the outlook for operating profit growth has been lowered to 10-16% from the previously anticipated 16-24%.</p><p>This revised guidance largely stems from a slower-than-expected penetration of its branded GLP-1 treatments, particularly in the United States, a market increasingly impacted by the persistent use of compounded GLP-1 alternatives.</p><div><div><div><p>Trending Investment Opportunities</p></div></div></div><h2>GLP-1 Drugs</h2><p>In a letter to the U.S. Food and Drug Administration (FDA) Commissioner <strong>Marty Makary</strong> on Friday, over 80 bipartisan members asked the agency to stop counterfeit and copycat versions of GLP-1 drugs like Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Zepbound from flooding the market.</p><p>The group wrote the letter urging immediate action against the rising threat of illegal, counterfeit anti-obesity medications entering the U.S. </p><p>The group urged the FDA to issue warning letters, pursue civil enforcement, and monitor non-compliant online retailers and compounding pharmacies selling unapproved weight-loss drugs.</p><p>In April, after media reports on <strong>Hims &amp; Hers Inc.</strong> <span>HIMS</span> partnering with the company, Eli Lilly said in a statement that it has no affiliation with Hims &amp; Hers.</p><p>Zepbound (tirzepatide) can be prescribed by any licensed healthcare professional. People who are commercially insured with coverage for Zepbound may be eligible to pay as little as $25.</p><h2>Trial Data</h2><p>On Tuesday, Eli Lilly also released topline results from the Phase 3 BRUIN CLL-314 trial of Jaypirca (pirtobrutinib) versus Imbruvica (ibrutinib) in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).</p><p><strong>Johnson &amp; Johnson’s</strong> <span>JNJ</span> Imbruvica is a covalent BTK inhibitor.</p><p>The study enrolled patients with treatment-naïve CLL/SLL and those previously treated but were BTK inhibitor-naïve.</p><p>The study met its primary endpoint of non-inferiority on overall response rate (ORR) as assessed by an independent review committee (IRC) in both the pre-treated and intent-to-treat populations.</p><p>ORR favored pirtobrutinib with a nominal P-value for superiority (p &lt;0.05). Progression-free survival (PFS), a key secondary endpoint, was not yet mature at this analysis, but was trending toward pirtobrutinib.</p><p>BRUIN CLL-314 is the first ever head-to-head trial versus ibrutinib in CLL to include treatment-naïve patients.</p><p>The overall safety profile of pirtobrutinib in BRUIN CLL-314 was similar to previously reported trials. Detailed results will be presented at a medical congress later in 2025.</p><p>These data build on the previously reported positive results from the BRUIN Phase 1/2 trial and the Phase 3 BRUIN CLL-321 trial, the first randomized, controlled study ever conducted in an exclusively post-covalent BTK inhibitor population.</p><p>The BRUIN CLL-313 Phase 3 study of pirtobrutinib versus chemoimmunotherapy in treatment naïve CLL/SLL is expected to read out later in 2025 and combined with the results of BRUIN CLL-314, will form the basis of regulatory submissions globally.</p><p><strong>Price Action:</strong> LLY stock is down 4.93% at $768.27 at the last check on Tuesday.</p><ul> <li><strong><em>SoFi Technologies Stock Surges On ‘Exceptional’ Q2 Earnings, Raised Guidance</em></strong></li> </ul><p><em>Image Via Shutterstock</em></p></div></div></div>

<p>Eli Lilly and Co. (LLY) stock fell 4.93% to $768.27 on Tuesday, influenced by Novo Nordisk's reduced 2025 financial outlook for its weight loss drugs. Novo Nordisk lowered its sales growth forecast to 8-14% from 13-21%, citing slower market penetration. Additionally, over 80 bipartisan members urged the FDA to combat counterfeit GLP-1 drugs. Eli Lilly also announced positive topline results from its Phase 3 BRUIN CLL-314 trial for Jaypirca (pirtobrutinib) against Imbruvica (ibrutinib) in chronic lymphocytic leukemia, meeting its primary endpoint.</p>

What's Going On With Eli Lilly Stock On Tuesday?